Key Record Dates
| ClinicalTrials.gov Identifier: | NCT02804763 |
|---|---|
| Brief Title: | A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus |
| First Submitted : | June 14, 2016 |
| First Submitted that Met QC Criteria : | June 14, 2016 |
| First Posted : | June 17, 2016 (Estimate) |
| Results First Submitted : | April 19, 2021 |
| Results First Submitted that Met QC Criteria : | June 7, 2021 |
| Results First Posted : | June 30, 2021 |
| Certification/Extension First Submitted : | June 19, 2019 |
| Certification/Extension First Submitted that Met QC Criteria : | June 19, 2019 |
| Certification/Extension First Posted : | June 21, 2019 |
| Last Update Submitted that Met QC Criteria : | June 7, 2021 |
| Last Update Posted : | June 30, 2021 |